Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11807MR)

This product GTTS-WQ11807MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Breast Cancer, Colorectal Cancer (CRC), Non-Small Cell Lung Cancers (NSCLC), Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ11807MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12635MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ2431MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ12250MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ14681MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ7784MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ15926MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ6629MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ10595MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY3300054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW